Jiaming Lai

机构：Sun Yat-sen University, The First Affiliated Hospital, Sun Yat-sen University

发表论文 24 篇 · 总被引 281 次 · h-index 7

代表论文

• Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study (2021 · Journal of Cancer Research and Clinical Oncology · 被引 114)
• Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis (2023 · Biomolecules · 被引 63)
• Mechanisms and Influence of Octreotide-Induced Regulation of Somatostatin Receptor 2 on Hepatocellular Carcinoma (2009 · Chemotherapy · 被引 25)
• Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study (2023 · Journal of Hepatocellular Carcinoma · 被引 24)
• Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer (2025 · JAMA Oncology · 被引 13)
• TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study (2024 · Frontiers in Immunology · 被引 13)